ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types EVOLUTION 3 feasibility study demonstrates improved time in range using ...

ACTON, Mass., June 06, 2026--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Findings from the STRIVE study indicated improved glycaemic control with Omnipod 6 compared to Omnipod 5.

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced new clinical results ...

First participant enrolled in randomized control trial designed to demonstrate safety and efficacy of Insulet’s fully closed-loop automated insulin delivery system versus standard therapy Unique ...

Please provide your email address to receive an email when new articles are posted on . The FDA has cleared the first tubeless hybrid closed-loop insulin delivery system for people with type 1 ...

A closed-loop system—commonly referred to as an artificial pancreas—could one day manage a user’s diabetes around the clock, eliminating the need for fingersticks, regular check-ins with a glucose ...

Closed-loop control systems of insulin delivery may improve glycemic outcomes in young children with type 1 diabetes. The efficacy and safety of initiating a closed-loop system virtually are unclear.